Abstract:Alpers' syndrome is an early-onset neurodegenerative disorder usually caused by biallelic pathogenic variants in the gene encoding the catalytic subunit of polymerase-gamma (POLG), which is essential for mitochondrial DNA (mtDNA) replication. The disease is progressive, incurable, and inevitably it leads to death from drug-resistant status epilepticus. The neurological features of Alpers' syndrome are intractable epilepsy and developmental regression, with no effective treatment; the underlying mechanisms are still elusive, partially due to lack of good experimental models. Here, we generated the patient derived induced pluripotent stem cells (iPSCs) from one Alpers' patient carrying the compound heterozygous mutations of A467T (c.1399G>A) and P589L (c.1766C>T), and further differentiated them into cortical organoids and neural stem cells (NSCs) for mechanistic studies of neural dysfunction in Alpers' syndrome. Patient cortical organoids exhibited a phenotype that faithfully replicated the molecular changes found in patient postmortem brain tissue, as evidenced by cortical neuronal loss and depletion of mtDNA and complex I (CI). Patient NSCs showed mitochondrial dysfunction leading to ROS overproduction and downregulation of the NADH pathway. More importantly, the NAD<sup>+</sup> precursor nicotinamide riboside (NR) significantly ameliorated mitochondrial defects in patient brain organoids. Our findings demonstrate that the iPSC model and brain organoids are good <i>in vitro</i> models of Alpers' disease; this first-in-its-kind stem cell platform for Alpers' syndrome enables therapeutic exploration and has identified NR as a viable drug candidate for Alpers' disease and, potentially, other mitochondrial diseases with similar causes.

Establishment of an iPSC line (BCHNDi001-A) from a patient with nicotinamide nucleotide repair system deficiency caused by biallelic NAXD mutations

Establishment of Induced Pluripotent Stem Cell Line (Zzui009-A) from an Alzheimer's Disease Patient Carrying a PSEN1 Gene Mutation

Establishment of an Induced Pluripotent Stem Cell Line (Zjulli004-A) from a Hypertrophic Cardiomyopathy Patient Carrying MYBPC3/c.3764C>A Mutation

Establishment of Induced Pluripotent Stem Cell Line (Zzui010-A) from an Alzheimer's Disease Patient Carrying an APP Gene Mutation.

Establishment of an iPSC line from a NDD patient with a heterozygous mutation in the CTNNB1 gene

Neural stem cells for disease modeling and evaluation of therapeutics for infantile (CLN1/PPT1) and late infantile (CLN2/TPP1) neuronal ceroid lipofuscinoses

Generation and characterization of PBMCs-derived human induced pluripotent stem cell (iPSC) line SDQLCHi055-A from a patient with NEDSDV carrying a heterozygote mutation in the CTNNB1 gene

Establishment of an Induced Pluripotent Stem Cell (ipsc) Line (Inndsui004-A) from a Patient with Congenital Nemaline Myopathy

Generation of Two Induced Pluripotent Stem Cell Lines (Xachi0010-A, XACHi0011-A) from a Chinese Family with Combined Oxidative Phosphorylation Deficiency Carrying Homozygous and Heterozygous C1QBP-L275F Mutation.

Generation and Characterization of Ipsc Lines (BCH001) from a Boy with Intron 14 Mutation in the Ret Proto-Oncogene (RET) Gene.

Generation of a Human Induced Pluripotent Stem Cell Line (Sbwchi001-A) from a Patient with NEDSDV Carrying a Pathogenic Mutation in CTNNB1 Gene.

Generation of an Induced Pluripotent Stem Cell Line (FDCHI007-A) Derived from a Patient with Developmental and Epileptic Encephalopathy Type 31 Carrying Heterozygous C.545c > A Mutation in DNM1 Gene

Human induced pluripotent stem cell line (FDHSi005-A) derived from a patient with a deep intronic variant in the GNE gene

Establishment of a transgene-free iPS cell line (SDCHi002-A) from a young patient bearing a NPRL3 mutation and suffering from Epilepsy

Generation of Induced Pluripotent Stem Cell Line, ZJUCHi002-A, from Charcot-Marie-Tooth Disease Type 2A (CMT2A) Patient with a Mutation of C.752c>t in MFN2

Establishment of Ipsc Line from a Chinese Infant (Xachi012-A) with Jervell and Lange-Nielsen Syndrome Carrying Combined KCNQ1 Frameshift C.431delc(p.i145sfs*92) and Nonsense C.1175g > A (p.w392x) Variants and Two Ipsc Lines from the Parents (Xachi013-A, XACHi014-A).

Establishment Of An Induced Pluripotent Stem Cell Line (Zjshi001-A) From A Patient With Epileptic Encephalopathy Carrying Kcnb1 Glu330asp Mutation

The NAD + Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC derived Cortical Organoid of Alpers' Disease

Derivation of an induced pluripotent stem cell line (FDCHi014-A) from PBMCs of a seven-year-old patient with a truncating NOVA2 variant (c.625del)

Establishment of a transgene-free iPS cell line (SDCHi003-A) from a young patient bearing a NPRL2 mutation and suffering from Epilepsy

Derivation of Ipsc Lines from Two Patients with Autism Spectrum Disorder Carrying NRXN1α Deletion (Nuigi041-A, NUIG041-B; NUIGi045-A) and One Sibling Control (Nuigi042-A, NUIGi042-B)